Avidity Partners Management LP Sells 12,200 Shares of Thermo Fisher Scientific Inc. $TMO

Avidity Partners Management LP lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 64.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 6,700 shares of the medical research company’s stock after selling 12,200 shares during the period. Thermo Fisher Scientific makes up about 1.1% of Avidity Partners Management LP’s investment portfolio, making the stock its 19th largest position. Avidity Partners Management LP’s holdings in Thermo Fisher Scientific were worth $3,882,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Brown Advisory Inc. lifted its stake in shares of Thermo Fisher Scientific by 1.3% in the 4th quarter. Brown Advisory Inc. now owns 89,219 shares of the medical research company’s stock worth $51,698,000 after purchasing an additional 1,170 shares during the period. Brasada Capital Management LP lifted its stake in shares of Thermo Fisher Scientific by 20.8% in the 4th quarter. Brasada Capital Management LP now owns 9,453 shares of the medical research company’s stock worth $5,585,000 after purchasing an additional 1,627 shares during the period. Black Creek Investment Management Inc. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $348,000. AFT Forsyth & Company Inc. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $2,175,000. Finally, Atlas Capital Advisors Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $195,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO opened at $468.80 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The company has a 50 day simple moving average of $479.14 and a two-hundred day simple moving average of $527.68. The firm has a market cap of $174.22 billion, a P/E ratio of 25.77, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the firm posted $5.15 EPS. The company’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Finally, Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday. They issued a “neutral” rating and a $510.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.